

1 **Evaluating the effect of metabolic traits on oral and oropharyngeal**
2 **cancer risk using Mendelian randomization**

3

4 Mark Gormley, BDS* ^{1,2}, Tom Dudding, PhD², Steven J Thomas, PhD², Jessica Tyrrell, PhD³,

5 Andrew R Ness, PhD⁴, Miranda Pring, PhD², Danny Legge, PhD⁵, George Davey Smith, FRS¹,

6 Rebecca C Richmond, PhD¹, Emma E Vincent, PhD^{1,5§}, Caroline Bull, PhD^{1,5§}

7 ¹ MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol,

8 Bristol, UK.

9 ² Bristol Dental Hospital and School, University of Bristol, Bristol, UK.

10 ³ University of Exeter Medical School, RILD Building, RD&E Hospital, Exeter, UK.

11 ⁴ University Hospitals Bristol and Weston NHS Foundation Trust National Institute for Health Research Bristol

12 Biomedical Research Centre, University of Bristol, Bristol, UK

13 ⁵ Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

14 § Joint senior authors

15 * Corresponding author: mark.gormley@bristol.ac.uk

16

17

18

19

20 **Abstract**

21

22 A recent World Health Organization report states that at least 40% of all cancer cases may
23 be preventable, with smoking, alcohol consumption and obesity identified as three of the
24 most important modifiable lifestyle factors. Given the significant decline in smoking rates,
25 particularly within developing countries, other potentially modifiable risk factors for head
26 and neck cancer warrant investigation. Obesity and related metabolic disorders such as type
27 2 diabetes and hypertension have been associated with head and neck cancer risk in
28 multiple observational studies. However, obesity has also been correlated with smoking,
29 with bias, confounding or reverse causality possibly explaining these findings. To overcome
30 the challenges of observational studies, we conducted two-sample Mendelian
31 randomization (inverse variance weighted (IVW) method) using genetic variants which were
32 robustly associated with obesity, T2D and hypertension in genome-wide association studies
33 (GWAS). Outcome data was taken from the largest available GWAS of 6,034 oral and
34 oropharyngeal cases, with 6,585 controls. We found limited evidence of a causal effect of
35 genetically proxied body mass index (OR IVW = 0.89, 95%CI 0.72–1.09, $p = 0.26$ per 1 SD in
36 BMI (4.81 kg/m²)) on oral and oropharyngeal cancer risk. Similarly, there was limited
37 evidence for related traits including type 2 diabetes and hypertension. Smoking appears to
38 act as a mediator in the relationship between obesity and head and neck cancer.

39

40

41

42

43 **Introduction**

44

45 Head and neck squamous cell carcinoma (HNC), which includes cancers of the oral cavity
46 and oropharynx is the 7th most common cancer, accounting for more than 660,000 new
47 cases and 325,000 deaths annually worldwide (Johnson et al., 2020; Sung et al., 2021).

48 Established risks include tobacco use, alcohol consumption (Hashibe et al., 2009) and
49 human papillomavirus (HPV) infection, mainly associated with oropharyngeal cancer and
50 thought to be sexually transmitted (Gillison, Chaturvedi, Anderson, & Fakhry, 2015). A

51 recent World Health Organization (WHO) report states that at least 40% of all cancer cases
52 may be preventable, with smoking, alcohol consumption and obesity identified as three of
53 the most important modifiable lifestyle factors (World Health Organization (WHO), 2022).

54 Smoking behaviour is declining, particularly in developing countries and it has been
55 projected that obesity could even supersede smoking as the primary driver of cancer in the
56 coming decades (World Health Organization (WHO), 2022). Despite changes in smoking
57 rates, the incidence of HNC continues to rise and a changing aetiology has been proposed
58 (Conway, 2018; Thomas, Penfold, Waylen, & Ness, 2018). Therefore, less established risks
59 such as obesity and its related metabolic traits warrant investigation in HNC. However,
60 obesity has been correlated with other HNC risk factors such as smoking (Carreras-Torres et
61 al., 2018), alcohol (Alice R. Carter et al., 2019) and educational attainment (A. R. Carter et
62 al., 2019), meaning independent effects are difficult to establish.

63

64 Obesity is now considered to increase the risk of at least 13 different types of cancer
65 including breast, colorectal, gastric and oesophageal (Centers for Disease Control and
66 Prevention, 2021), but the effect on HNC risk remains unclear (World Health Organization

67 (WHO), 2022). Public health strategies have been unsuccessful in addressing the current
68 obesity epidemic at the population level, which could result in more cancer cases in the
69 years to come (Davey, 2004). Obesity and related metabolic traits such as type 2 diabetes
70 (T2D), hypertension and dyslipidaemia have all been associated with head and neck cancer
71 in multiple observational studies. In the largest pooled analysis, obesity defined by higher
72 body mass index (BMI) was associated with a protective effect for HNC in current smokers
73 (hazard ratio (HR) 0.76, 95% confidence intervals (95%CI) 0.71–0.82, $p < 0.0001$, per
74 5 kg/m^2) and conversely, a higher risk in never smokers (HR 1.15, 95%CI 1.06–1.24 per
75 5 kg/m^2 , $p < 0.001$) (Gaudet et al., 2015). In the same study, a greater waist circumference
76 (WC) (HR 1.04, 95%CI 1.03–1.05 per 5 cm , $p < 0.001$) and waist-to-hip ratio (WHR)
77 (HR 1.07, 95%CI 1.05–1.09 per 0.1 unit, $p < 0.001$) were associated with increased HNC risk,
78 which did not vary by smoking status (Gaudet et al., 2015). However, more recent cohort
79 studies have failed to show a clear association between BMI and HNC (Cao et al., 2020; Diaz
80 et al., 2021; Gribsholt et al., 2020; Jiang et al., 2021; Ward et al., 2017). A meta-analysis of
81 observational studies investigating T2D with oral and oropharyngeal subsites, showed an
82 increased risk ratio (RR) of 1.15, 95%CI 1.02–1.29, $P_{\text{heterogeneity}} = 0.277$ (Gong, Wei, Yu, &
83 Pan, 2015), a result which is consistent with more recent independent cohorts (Jiang et al.,
84 2021; H.-B. Kim, Kim, Han, & Joo, 2021; S.-Y. Kim, Han, & Joo, 2019; Saarela et al., 2019).
85 Hypertension (defined as a systolic blood pressure (SBP) $> 130 \text{ mmHg}$ or diastolic blood
86 pressure (DBP) $> 85 \text{ mmHg}$), has been correlated with head and neck cancer risk across
87 multiple studies (Christakoudi et al., 2020; H.-B. Kim et al., 2021; S.-Y. Kim et al., 2019; Seo,
88 Kim, Park, Han, & Joo, 2020; Stocks et al., 2012). Nonetheless, selection bias, confounding,
89 or reverse causation may explain the findings from these studies.

90

91 Mendelian randomization (MR) is an analytical approach which attempts to overcome the
92 challenges of conventional epidemiological studies. The method uses germline genetic
93 single nucleotide polymorphisms (SNPs), which are randomly assorted during meiosis (and
94 fixed at conception), to estimate the causal effects of exposures on disease outcomes
95 (Davey Smith & Hemani, 2014; Sanderson et al., 2022; Smith & Ebrahim, 2003). Using MR,
96 we recently found limited evidence for a role of circulating lipid traits in oral and
97 oropharyngeal cancer risk (Gormley et al., 2021), however other metabolic traits remain
98 untested in an MR framework. Here, we employ a two-sample MR approach, integrating
99 summary-level genetic data from the largest available GWAS for metabolic traits, including
100 obesity measures (BMI, WC, WHR), glycaemic traits (T2D, glycated haemoglobin (HbA_{1c}),
101 fasting glucose (FG), fasting insulin (FI)), and blood pressure (SBP, DBP) to evaluate their
102 causal effect on oral and oropharyngeal cancer risk. Given the potential correlation of
103 metabolic traits and established HNC risk factors, further evaluation of instrument-risk
104 factor effects including smoking, alcohol, risk tolerance (as a proxy for sexual behaviour),
105 and educational attainment was carried out using MR.


106

107 **Methods**

108

109 Two-sample MR was performed using published summary-level data from the largest
110 available GWAS for each metabolic trait. MR makes three key assumptions, as described in
111 **Figure 1** (Davey Smith & Hemani, 2014; Smith & Ebrahim, 2003).

112



113

114 **Figure 1.** Directed acyclic graph (DAG) depicting Mendelian randomization applied to this
115 study

116

117 Genetic variants (G) act as proxies or instruments to investigate if an exposure (X), is associated with a trait
118 e.g., body mass index or disease outcome (Y) e.g., oral/oropharyngeal cancer. Causal inference can be made
119 between X and Y if the following conditions are upheld:

120 (1) G is a valid instrument, reliably associated with X ('relevance');

121 (2) no measured (C) or unmeasured (U) confounding of the association between G and the Y
122 ('exchangeability');

123 (3) there is no independent association of G with Y, except through X ('exclusion restriction principle').

124

125 **Exposure summary statistics for metabolic traits**

126

127 To instrument metabolic traits, we selected genetic variants associated ($p < 5 \times 10^{-8}$) with
128 traits of interest identified by previously conducted GWAS (**Supplementary file 1**). Clumping
129 was performed to ensure single nucleotide polymorphisms (SNPs) in each instrument were
130 independent (linkage disequilibrium $R^2 < 0.001$). Following clumping, genetic instruments

131 were comprised of: 312 SNPs for BMI, from a GWAS meta-analysis of 806,834 individuals of
132 European ancestry, including the Genetic Investigation of ANthropometric Traits (GIANT)
133 consortium and UK Biobank (Pulit et al., 2019); and 209 SNPs for WHR extracted from the
134 same GWAS in 697,734 individuals (Pulit et al., 2019). 45 SNPs for WC were taken from a
135 GWAS meta-analysis describing 224,459 individuals of mainly European ancestry (Shungin et
136 al., 2015); 275 SNPs for T2D from the DIAMANTE (DIAbetes Meta-ANalysis of Trans-Ethnic
137 association studies) consortium of 228,499 cases and 1,178,783 controls (Vujkovic et al.,
138 2020); 33 SNPs for FG and 18 SNPs for FI, obtained from a GWAS published by the MAGIC
139 (Meta-Analyses of Glucose and Insulin-Related Traits) Consortium (N = 151,188 and 105,056
140 individuals, respectively) (Lagou et al., 2021); 58 SNPs for HbA_{1c}, taken from a meta-analyses
141 of 159,940 individuals from 82 cohorts of European, African, East Asian, and South Asian
142 ancestry (Wheeler et al., 2017); Finally, 105 and 78 SNPs for SBP and DBP, respectively, were
143 extracted from a GWAS meta-analysis of over 1 million participants in UK Biobank and the
144 International Consortium of Blood Pressure Genome Wide Association Studies (ICBP)
145 (Evangelou et al., 2018) (**Supplementary file 1**).

146

147 **Outcome summary statistics for oral and oropharyngeal cancer**

148

149 We estimated the effects of metabolic traits on risk of oral and oropharyngeal cancer by
150 extracting exposure SNPs (**Supplementary file 1**) from the largest available GWAS
151 performed on 6,034 cases and 6,585 controls from 12 studies which were part of the
152 Genetic Associations and Mechanisms in Oncology (GAME-ON) Network (Lesseur et al.,
153 2016). Full details of the included studies, as well as the genotyping and imputation
154 performed, have been described previously (Dudding et al., 2018; Lesseur et al., 2016). In

155 brief, the study population included participants from Europe (45.3%), North America
156 (43.9%) and South America (10.8%). Cancer cases comprised the following the International
157 Classification of Diseases (ICD) codes: oral cavity (C02.0-C02.9, C03.0-C03.9, C04.0-C04.9,
158 C05.0-C06.9) oropharynx (C01.9, C02.4, C09.0-C10.9), hypopharynx (C13.0-C13.9),
159 overlapping (C14 and combination of other sites) and 25 cases with unknown ICD code
160 (other). A total of 954 individuals with cancers of hypopharynx, unknown code or
161 overlapping cancers were excluded. Genomic DNA isolated from blood or buccal cells was
162 genotyped at the Center for Inherited Disease Research (CIDR) using an Illumina OncoArray,
163 custom designed for cancer studies by the OncoArray Consortium (Consortium, 2013).
164 Principle components analysis was performed using approximately 10,000 common markers
165 in low LD ($r^2 < 0.004$), minor allele frequency (MAF) > 0.05 and 139 population outliers were
166 removed.

167

168 Given the differential association of potential risk factors at each subsite (i.e. smoking,
169 alcohol and HPV infection)(Thomas et al., 2018), we performed stratified MR analyses for
170 oral and oropharyngeal cancer to evaluate potential heterogeneity in effects. For this, we
171 used GWAS summary data on a subset of 2,990 oral and 2,641 oropharyngeal cases and the
172 6,585 common controls in the GAME-ON GWAS (Lesseur et al., 2016).

173

174 **Statistical analysis**

175

176 Two-sample MR was conducted using the “TwoSampleMR” package in R (version 3.5.3), by
177 integrating SNP associations for each metabolic trait (exposure, sample 1) with those for
178 oral and oropharyngeal cancer in GAME-ON (outcome, sample 2). We only used genetic

179 variants reaching GWAS significance ($p < 5 \times 10^{-8}$). The nearest gene was identified using
180 SNPsnap and a distance of +/- 500 kb (Pers, Timshel, & Hirschhorn, 2014). Firstly, metabolic
181 trait-associated SNPs were extracted from oral and oropharyngeal cancer summary
182 statistics. Exposure and outcome summary statistics were harmonised using the
183 *"harmonise_data"* function of the TwoSampleMR package so that variant effect estimates
184 corresponded to the same allele. Palindromic SNPs were identified and corrected using
185 allele frequencies where possible (alleles were aligned when minor allele frequencies were <
186 0.3, or were otherwise excluded). For each SNP in each exposure, individual MR effect-
187 estimates were calculated using the Wald method (SNP-outcome beta/SNP-exposure beta)
188 (Wald, 1940). Multiple SNPs were then combined into multi-allelic instruments using
189 random-effects inverse-variance weighted (IVW) meta-analysis.

190

191 IVW estimates may be vulnerable to bias if genetic instruments are invalid and are only
192 unbiased in the absence of horizontal pleiotropy or when horizontal pleiotropy is balanced
193 (Hemani, Bowden, & Smith, 2018). We therefore performed additional sensitivity analyses
194 to evaluate the potential for unbalanced horizontal pleiotropy using weighted median
195 (Bowden, Smith, Haycock, & Burgess, 2016), weighted mode (Hartwig, Smith, & Bowden,
196 2017) and MR-Egger (Bowden, Davey Smith, & Burgess, 2015) methods which are described
197 in detail elsewhere (Lawlor DA, 2019). In short, the weighted median stipulates that at least
198 50% of the weight in the analysis stems from valid instruments. Weighted mode returns an
199 unbiased estimate of the causal effect if the cluster with the largest weighted number of
200 SNPs for the weighted model are all valid instruments. Instruments are weighted by the
201 inverse variance of the SNP-outcome association (Hartwig et al., 2017).

202

203 Finally, MR-Egger provides reliable effect estimates even if variants are invalid and the
204 Instrument Strength Independent of Direct Effect (InSIDE) assumption is violated (Bowden
205 et al., 2015). The InSIDE assumption states that the association between genetic instrument
206 and exposure should not be correlated with an independent path from instrument to the
207 outcome. In the presence of unbalanced pleiotropy when the InSIDE assumption is violated,
208 then the MR-Egger result may be biased (Lawlor DA, 2019). Gene variants must be valid
209 instruments and where there was evidence of violation of the negligible measurement error
210 (NOME) assumption (Bowden, Del Greco, et al., 2016), this was assessed using the I^2 statistic
211 and MR-Egger was performed with simulation extrapolation (SIMEX) correction for bias
212 adjustment (Bowden, Del Greco, et al., 2016). The variance of each trait explained by the
213 genetic instrument (R^2) was estimated and used to perform power calculations (Brion,
214 Shakhbazov, & Visscher, 2013). F-statistics were also generated. An F-statistic lower than 10
215 was interpreted as indicative of a weak instrument bias (Lawlor, Harbord, Sterne, Timpson,
216 & Davey Smith, 2008). To further assess the robustness of MR estimates, we examined
217 evidence of heterogeneity across individual SNPs using the Cochran Q-statistic, which
218 indicates the presence of invalid instruments (e.g., due to horizontal pleiotropy), if Q is
219 much larger than its degrees of freedom (No. of instrumental variables minus 1) (Bowden et
220 al., 2018). MR-PRESSO (Mendelian Randomization Pleiotropy RESidual Sum and Outlier) was
221 used to detect and correct for potential outliers (where Q-statistic $p < 0.05$) (Verbanck,
222 Chen, Neale, & Do, 2018).

223

224 **Instrument-risk factor effects**

225

226 Where there was evidence for an effect of a metabolic trait on oral or oropharyngeal cancer
227 risk in the primary MR analysis, we conducted further evaluation of the metabolic
228 instruments onto established HNC risk factors using two-sample MR. The largest available
229 GWAS were used for smoking initiation (a binary phenotype indicating whether an
230 individual had ever smoked in their life versus never smokers) (n=1,232,091) and alcoholic
231 drinks per week (defined as the average number of drinks per week aggregated across all
232 types of alcohol, n=941,280) from the GWAS and Sequencing Consortium of Alcohol and
233 Nicotine use (GSCAN) study (Liu et al., 2019). Summary statistics were also obtained from a
234 GWAS of general risk tolerance (n=939,908), derived from a meta-analysis of UK Biobank
235 (n=431,126) binary question “*Would you describe yourself as someone who takes risks?*”
236 and the 23andMe (n=508,782) question “*Overall, do you feel comfortable or uncomfortable*
237 *taking risks?*”. The GWAS of risk tolerance was based on one’s tendency or willingness to
238 take risks, making them more likely to engage in risk-taking behaviours more generally
239 (Karlsson Linner et al., 2019). A strong genetic correlation between sexual behaviours and
240 risk tolerance has been shown previously (Gormley et al., 2022). Finally, given the known
241 association between HNC and lower socioeconomic position, we used MR to examine
242 educational attainment (defined by years of schooling) (J. Lee et al., 2018). Outcome beta
243 estimates reflect the standard deviation of the phenotype.

244

245 **Results**

246

247 F-statistics of genetic instruments for metabolic traits ranged from 33.3 – 133.6, indicating
248 sufficient instrument strength for MR analyses (**Supplementary file 2 – table S1**). Genetic
249 instruments were estimated to explain between 0.5% (FI) and 4% (BMI) of their respective

250 metabolic trait (**Supplementary file 2 – table S1**). Based on the results of prior
251 observational studies we would expect to detect OR of >1.10 for a clinically meaningful
252 effect of metabolic traits on oral and oropharyngeal cancer. **Supplementary file 2 – figure**
253 **S1A-C** displays power estimates for MR analyses. In analyses where BMI was the exposure,
254 we had 70% power to detect an association with an OR of 1.2 or more at an α of 0.05 for
255 combined oral and oropharyngeal cancer. Power was lower for other metabolic traits and
256 reduced when stratifying analyses by subsite (**Supplementary file 2 – figure S1B-C**).

257

258 *Estimated effect of adiposity on oral and oropharyngeal cancer risk*

259 There was limited evidence of an effect of higher BMI or WHR on combined oral and
260 oropharyngeal cancer (OR IVW = 0.89, 95%CI 0.72–1.09, $p = 0.26$, per 1 SD in BMI (4.81
261 kg/m²) and OR IVW = 0.98, 95%CI 0.74–1.29, $p = 0.88$, per 1 SD in WHR (0.10 unit)) (**Table 1,**
262 **Figure 2, Supplementary file 2 – figure S2-S3**). Results were consistent when analyses were
263 stratified by subsite (**Table 1**). WC, another measure of adiposity did show a protective
264 direction of effect (OR IVW = 0.73, 95%CI 0.52–1.02, $p = 0.07$, per 1 SD increase in WC (0.09
265 unit)), particularly in the oropharyngeal subsite (OR IVW = 0.66, 95%CI 0.43–1.01, $p = 0.06$,
266 per 1 SD increase in WC (0.09 unit)) (**Table 1, Figure 2, Supplementary file 2 – figure S4**).

267

268 *Estimated effect of glycaemic traits on oral and oropharyngeal cancer risk*

269 There was limited evidence for an effect of genetically-proxied T2D on combined oral and
270 oropharyngeal cancer (OR IVW = 0.92, 95%CI 0.84–1.01, $p = 0.09$, per 1-log unit higher odds
271 of T2D (**Table 1, Figure 2, Supplementary file 2 – figure S5**). Traits related to diabetes,
272 including HbA_{1c} resulted in a weak protective effect on combined oral and oropharyngeal
273 cancer risk (OR IVW = 0.56, 95%CI 0.32–1.00, $p = 0.05$, per 1-log-unit % higher HbA_{1c}), which

274 remained only in the oral subsite (OR IVW = 0.48, 95%CI 0.24–0.93, $p = 0.03$, per 1-log-unit
275 % higher HbA_{1c}) following stratification (**Table 1, Figure 2, Supplementary file 2 – figure S6**).
276 Conversely, there was limited evidence of an effect for FG (OR IVW = 1.06, 95%CI 0.68–1.66,
277 $p = 0.79$, per 1-log unit increase in mmol/L fasting glucose) (**Table 1, Figure 2,**
278 **Supplementary file 2 – figure S7**) or FI (OR IVW = 0.81, 95%CI 0.23–2.89, $p = 0.75$, per 1-log
279 unit increase in mmol/L fasting insulin) on combined oral and oropharyngeal cancer risk
280 (**Table 1, Figure 2, Supplementary file 2 – figure S8**)

281

282 *Estimated effect of increased blood pressure oral and oropharyngeal cancer risk*

283 Finally, there was limited evidence for an effect of SBP on risk of combined oral and
284 oropharyngeal cancer (OR IVW = 1.00, 95%CI 0.97–1.03, $p = 0.89$, per 1 unit mmHg increase
285 in systolic blood pressure) (**Table 1, Figure 2, Supplementary file 2 – figure S9**), which did
286 not change when stratified by subsite. However, there was some weak evidence for a
287 protective effect of DBP on risk of combined oral and oropharyngeal cancer (OR IVW = 0.93,
288 95%CI 0.87–1.00, $p = 0.05$, per 1 unit mmHg increase in diastolic blood pressure) (**Table 1,**
289 **Figure 2, Supplementary file 2 – figure S10**).

290 **Table 1.** Mendelian randomization results of genetically-proxied metabolic traits with risk of oral and oropharyngeal cancer in GAME-ON

291

Exposure	Outcome	Exposure/ Outcome source	Outcome N	Number of SNPs	IVW		Weighted median		Weighted mode		MR-Egger	
					OR (95%CI)	P	OR (95%CI)	P	OR (95%CI)	P	OR (95%CI)	P
BMI	Oral and oropharyngeal cancer combined	Pulit <i>et al.</i> GWAS/ GAME-ON	6,034	272	0.89 (0.72, 1.09)	0.26	0.71 (0.50, 1.00)	0.05	0.63 (0.37, 1.04)	0.07	0.66 (0.40, 1.10)	0.11
	Oral cancer		2,990	272	0.92 (0.71, 1.19)	0.53	0.83 (0.55, 1.28)	0.40	0.79 (0.38, 1.62)	0.52	0.75 (0.39, 1.41)	0.37
	Oropharyngeal cancer		2,641	272	0.89 (0.68, 1.15)	0.36	0.75 (0.50, 1.13)	0.17	0.53 (0.27, 1.03)	0.06	0.56 (0.29, 1.07)	0.08
WC	Oral and oropharyngeal cancer combined	Shungin <i>et al.</i> GWAS/ GAME-ON	6,034	43	0.73 (0.52, 1.02)	0.07	0.64 (0.40, 1.05)	0.08	0.67 (0.36, 1.26)	0.22	0.43 (0.17, 1.08)	0.08
	Oral cancer		2,990	43	0.82 (0.53, 1.26)	0.36	0.66 (0.36, 1.21)	0.18	0.67 (0.32, 1.39)	0.29	0.54 (0.17, 1.76)	0.31
	Oropharyngeal cancer		2,641	43	0.66 (0.43, 1.01)	0.06	0.56 (0.30, 1.05)	0.07	0.37 (0.17, 0.83)	0.02	0.30 (0.09, 0.98)	0.05
WHR	Oral and oropharyngeal cancer combined	Pulit <i>et al.</i> GWAS/ GAME-ON	6,034	176	0.98 (0.74, 1.29)	0.88	0.98 (0.64, 1.49)	0.92	0.95 (0.45, 2.00)	0.89	1.80 (0.87, 3.71)	0.11
	Oral cancer		2,990	176	1.18 (0.84, 1.65)	0.35	1.00 (0.58, 1.73)	0.99	0.69 (0.29, 1.67)	0.41	2.49 (1.02, 6.12)	0.05
	Oropharyngeal cancer		2,641	176	0.83 (0.59, 1.14)	0.25	0.88 (0.51, 1.50)	0.63	0.93 (0.37, 2.30)	0.87	1.19 (0.50, 2.86)	0.70
T2D	Oral and oropharyngeal cancer combined	Vujkovic <i>et al.</i> GWAS/ GAME-ON	6,034	254	0.92 (0.84, 1.01)	0.09	0.85 (0.74, 0.97)	0.02	0.84 (0.71, 1.01)	0.06	0.91 (0.77, 1.09)	0.31
	Oral cancer		2,990	254	0.94 (0.84, 1.05)	0.27	0.84 (0.72, 0.99)	0.04	0.82 (0.66, 1.02)	0.08	0.88 (0.71, 1.08)	0.22
	Oropharyngeal cancer		2,641	254	0.94 (0.84, 1.05)	0.27	0.89 (0.73, 1.10)	0.29	1.02 (0.80, 1.30)	0.88	1.00 (0.81, 1.24)	0.99
HbA _{1c}	Oral and oropharyngeal cancer combined	Wheeler <i>et al.</i> GWAS/	6,034	37	0.56 (0.32, 1.00)	0.05	0.52 (0.23, 1.20)	0.12	0.54 (0.24, 1.21)	0.14	0.37 (0.13, 1.05)	0.07

		GAME-ON (Lesseur et al., 2016)										
	Oral cancer		2,990	37	0.48 (0.24, 0.93)	0.03	0.51 (0.18, 1.41)	0.19	0.44 (0.15, 1.29)	0.14	0.30 (0.09, 1.03)	0.06
	Oropharyngeal cancer		2,641	37	0.66 (0.31, 1.40)	0.28	0.49 (0.15, 1.57)	0.23	0.57 (0.18, 1.85)	0.35	0.43 (0.11, 1.68)	0.23
FG	Oral and oropharyngeal cancer combined	Lagou <i>et al.</i> GWAS/ GAME-ON (Lesseur et al., 2016)	6,034	28	1.06 (0.68, 1.66)	0.79	1.20 (0.62, 2.30)	0.59	1.13 (0.60, 2.12)	0.71	1.11 (0.48, 2.56)	0.80
	Oral cancer		2,990	28	1.05 (0.58, 1.92)	0.87	1.15 (0.48, 2.72)	0.75	0.99 (0.44, 2.23)	0.99	1.25 (0.39, 4.01)	0.70
	Oropharyngeal cancer		2,641	28	1.39 (0.77, 2.51)	0.28	1.24 (0.51, 3.03)	0.63	1.36 (0.59, 3.18)	0.48	1.38 (0.45, 4.18)	0.58
FI	Oral and oropharyngeal cancer combined	Lagou <i>et al.</i> GWAS/ GAME-ON	6,034	17	0.81 (0.23, 2.89)	0.75	0.75 (0.20, 2.87)	0.68	0.60 (0.03, 10.79)	0.74	0.11 (0.001, 22.47)	0.43
	Oral cancer		2,990	17	0.96 (0.22, 4.16)	0.96	0.46 (0.08, 2.47)	0.37	0.45 (0.01, 19.02)	0.68	0.21 (0.0004, 107.21)	0.63
	Oropharyngeal cancer		2,641	17	0.68 (0.16, 2.87)	0.59	0.66 (0.12, 3.67)	0.63	0.48 (0.05, 4.99)	0.55	0.09 (0.0002, 40.04)	0.45
SBP	Oral and oropharyngeal cancer combined	Evangelou <i>et al.</i> GWAS/ GAME-ON (Lesseur et al., 2016)	6,034	83	1.00 (0.97, 1.03)	0.89	0.99 (0.94, 1.03)	0.55	0.98 (0.88, 1.09)	0.66	1.06 (0.92, 1.23)	0.39
	Oral cancer		2,990	83	1.01 (0.96, 1.06)	0.74	0.99 (0.93, 1.04)	0.65	0.95 (0.84, 1.08)	0.48	1.09 (0.90, 1.33)	0.37
	Oropharyngeal cancer		2,641	83	0.99 (0.95, 1.03)	0.65	0.99 (0.94, 1.05)	0.77	1.00 (0.88, 1.13)	0.94	1.03 (0.87, 1.23)	0.71
DBP	Oral and oropharyngeal cancer combined	Evangelou <i>et al.</i> GWAS/ GAME-ON	6,034	64	0.93 (0.87, 1.00)	0.05	0.94 (0.86, 1.04)	0.22	1.10 (0.88, 1.38)	0.42	0.99 (0.80, 1.24)	0.95
	Oral cancer		2,990	64	0.95 (0.87, 1.04)	0.26	0.96 (0.86, 1.07)	0.45	1.17 (0.88, 1.56)	0.28	0.97 (0.74, 1.27)	0.81
	Oropharyngeal cancer		2,641	64	0.92 (0.84, 1.00)	0.05	0.94 (0.84, 1.05)	0.29	1.10 (0.86, 1.41)	0.45	1.00 (0.75, 1.30)	0.93

292


293 Abbreviations: IVW, inverse variance weighted; OR, odds ratio; CI, confidence intervals; P, *p*-value; BMI, body mass index; WC, waist circumference; WHR, waist-hip ratio; T2D, type 2 diabetes mellitus; FG, fasting

294 glucose; FI, fasting insulin; HbA_{1c}, glycated haemoglobin; SBP, systolic blood pressure; DBP, diastolic blood pressure. OR are expressed per 1 standard deviation (SD) increase in genetically predicted BMI (4.81 kg/m²),

295 WC (0.09 unit), WHR (0.10 unit), T2D (1-log unit higher odds of T2D), FG (1-log unit increase in mmol/L fasting glucose), FI (1-log unit increase in mmol/L fasting insulin), HbA_{1c} (1-log-unit % higher glycated

296 haemoglobin), SBP (1 unit mmHg increase) and DBP (1 unit mmHg increase).

297 **Figure 2.** Mendelian randomization results of genetically-proxied metabolic disorders with
 298 risk of oral and oropharyngeal cancer including sensitivity analyses in GAME-ON
 299



300

301

302 Abbreviations: IVW, inverse variance weighted; OR, odds ratio with 95% confidence intervals; BMI, body mass index; WC, waist
 303 circumference; WHR, waist-hip ratio; T2D, type 2 diabetes mellitus; FG, fasting glucose; FI, fasting insulin; HbA1c, glycated haemoglobin;
 304 SBP, systolic blood pressure; DBP, diastolic blood pressure. OR are expressed per 1 standard deviation (SD) increase in genetically
 305 predicted BMI (4.81 kg/m²), WC (0.09 unit), WHR (0.10 unit), T2D (1-log unit higher odds of T2D), FG (1-log unit increase in mmol/L
 306 fasting glucose), FI (1-log unit increase in mmol/L fasting insulin), HbA1c (1-log-unit % higher glycated haemoglobin), SBP (1 unit mmHg
 307 increase) and DBP (1 unit mmHg increase).

308

309 Sensitivity analyses

310

311 We conducted MR Egger, weighted median, and weighted mode analyses in addition to IVW
 312 (Table 1, Figure 2). The results of these analyses generally followed the same pattern as the

313 IVW results reported above, however, there were a number of exceptions. The results for
314 HbA_{1c} were not robust to sensitivity testing ($p > 0.05$ across methods) (**Table 1, Figure 2**). In
315 the analysis of T2D on combined oral and oropharyngeal cancer, the weighted median result
316 provided evidence for a weak protective effect (OR weighted median 0.85, 95%CI 0.74–0.97,
317 $p = 0.02$). This effect appeared mainly in the oral subsite (OR weighted median 0.84, 95%CI
318 0.72–0.99, $p = 0.04$). Furthermore, in the analysis of WC on oropharyngeal cancer risk, the
319 weighted mode supported IVW result, providing evidence of a protective effect (OR
320 weighted mode 0.37, 95%CI 0.17–0.83, $p = 0.02$) (**Table 1, Figure 2**).

321

322 There was clear evidence of heterogeneity in the SNP effect estimates OR IVW and MR
323 Egger regression for WHR (Q IVW = 213.04, $p = 0.03$; Q MR Egger = 209.24, $p = 0.04$), T2D (Q
324 IVW = 328.24, $p < 0.01$; Q MR Egger = 328.21, $p < 0.01$), FI (Q IVW = 32.87, $p < 0.01$; Q MR
325 Egger = 31.63, $p < 0.01$) and DBP (Q IVW = 95.82, $p < 0.01$; Q MR Egger = 95.22, $p < 0.01$)
326 (**Supplementary file 2 – table S2**). MR-Egger intercepts were not strongly indicative of
327 directional pleiotropy (**Supplementary file 2 – table S3**), but there were outliers present on
328 visual inspection of scatter plots (**Supplementary file 2 – figures S11-19**). MR-PRESSO
329 identified 19 outliers for BMI, 2 outliers for WC, 12 outliers for WHR, 23 outliers for T2D, 4
330 outliers for HbA_{1c}, 1 outlier for FG, 3 outliers for FI, 5 outliers for SBP, 7 outliers for DBP
331 (**Supplementary file 2 – tables S4-5**). When correcting for these outliers, this yielded effects
332 consistent with the primary IVW analysis except for adiposity and T2D instruments, which
333 demonstrated a protective effect on combined oral and oropharyngeal cancer risk when
334 outliers were excluded: BMI (OR IVW = 0.77, 95%CI 0.62–0.94, $p = 0.01$, per 1 SD in BMI
335 (4.81 kg/m²)); WC (OR IVW = 0.65, 95%CI 0.47–0.89, $p = 0.01$, per 1 SD in WC (0.09 unit)),
336 and T2D (OR IVW = 0.91, 0.84–0.99, $p = 0.03$, per 1-log unit higher odds of T2D)

337 **(Supplementary file 2 – table S6)**. Where there was evidence of violation of the NOME
338 assumption for WC, FI, SBP and DBP (i.e., I^2 statistic <0.90) **(Supplementary file 2 – table**
339 **S7)**, MR-Egger was performed with SIMEX correction. SIMEX effects were consistent with
340 the null, except for SBP where an increased risk effect on combined oral and oropharyngeal
341 cancer was found (OR IVW = 1.15, 95%CI 1.05–1.26, $p < 0.01$, per 1 unit mmHg increase in
342 diastolic blood pressure) **(Supplementary file 2 – table S8)**.

343

344 *Evaluating instrument-risk factor effects*

345 Where there was some evidence for an effect of BMI, WC, WHR, T2D, HbA_{1c} and DBP on
346 oral and oropharyngeal cancer, we carried out further MR analysis to determine causal
347 effects of these metabolic instruments on established risk HNC risk factors. Obesity-related
348 measures showed a strong causal effect on the risk of smoking initiation: BMI (Beta IVW
349 0.21 (standard error (SE) 0.03), $p < 0.001$, per 1 SD increase in BMI (4.81 kg/m²)), WC (Beta
350 IVW 0.21 (SE 0.05), $p < 0.001$, per 1 SD increase in WC (0.09 unit)) and WHR (Beta IVW 0.18
351 (SE 0.03), $p < 0.001$, per 1 SD increase in WHR (0.10 unit)) **(Supplementary file 2 – table S9)**.

352 There was weaker evidence for an effect of BMI, WC, and genetic liability to T2D on
353 consumption of alcoholic drinks per week: BMI (Beta IVW -0.04 (SE 0.01), $p < 0.01$, per 1 SD
354 increase in BMI (4.81 kg/m²)), WC (Beta IVW -0.09 (SE 0.02), $p < 0.001$, per 1 SD increase in
355 WC (0.09 unit)) and T2D (Beta IVW -0.02 (SE 0.01), $p < 0.001$, per 1-log unit higher odds of
356 T2D). BMI (Beta IVW 0.04 (SE 0.01), $p < 0.001$, per 1 SD increase in BMI (4.81 kg/m²)) and
357 WHR (Beta IVW 0.04 (SE 0.02), $p = 0.02$, per 1 SD increase in WHR (0.10 unit)) were also
358 estimated to increase general risk tolerance. Similarly, increased BMI or WHR and genetic
359 liability to T2D were estimated to increase educational attainment (years of schooling): BMI
360 (Beta IVW -0.16 (SE 0.02), $p < 0.001$, per 1 SD increase in BMI (4.81 kg/m²)), WHR (Beta IVW

361 -0.11 (SE 0.02), $p < 0.001$, per 1 SD increase in WHR (0.10 unit)), and T2D (Beta IVW -0.02 (SE
362 0.01), $p < 0.01$, per 1-log unit higher odds of T2D). However, there was strong evidence of
363 both heterogeneity (**Supplementary file 2 – table S10**) and genetic pleiotropy
364 (**Supplementary file 2 – table S11**) across most instrument-risk factor effects. With the
365 exception of alcohol drinks per week, the estimated instrument-risk factor effects remained
366 unchanged following the removal of outlier SNPs detected by MR-PRESSO (**Supplementary
367 file 2 – table S12**).

368

369 **Discussion**

370

371 In this MR study we found limited evidence to support a causal role of genetically-predicted
372 metabolic traits in oral and oropharyngeal cancer, suggesting the risk may have been
373 previously overestimated in observational studies. Where weak evidence for an effect was
374 found (i.e., a protective effect of HbA_{1c}), these results were not robust to sensitivity analysis,
375 including outlier correction. There was also strong evidence for instrument-risk factor
376 effects, suggesting smoking may be a mediator between obesity and HNC.

377

378 There are several biological mechanisms linking metabolic traits and cancer, but these have
379 not been well explored in HNC (Gatenby & Gillies, 2004; Grimberg, 2003; Tseng, Lin, Lin, &
380 Weng, 2014). Dysregulated metabolism is likely linked to the probability a cancer develops
381 and progresses, given that tumours must adapt to satisfy the bioenergetic and biosynthetic
382 demands of chronic cell proliferation via metabolic reprogramming, enhancing or
383 suppressing the activity of metabolic pathways relative to that in benign tissue (DeNicola &

384 Cantley, 2015). In the largest pooled analysis of 17 case-control studies, BMI was associated
385 with a higher risk of overall HNC, but when stratified by subsite the effect was mainly in the
386 larynx (HR 1.42, 95%CI 1.19–1.70 per 5 kg/m², $p < 0.001$) (Gaudet et al., 2015). Laryngeal
387 cancer was not included in our study given that GWAS summary data were not available for
388 this subsite and future analysis of this region is therefore warranted. BMI effects on both
389 the oral (HR 1.10, 95%CI 0.97–1.25, $p = 0.14$) and oropharyngeal cancer (HR 0.98, 95%CI
390 0.84–1.14, $p = 0.77$) subsites were consistent with the effects found in our study (oral
391 cancer OR 0.92, 95%CI 0.71–1.19, $p = 0.53$; oropharyngeal cancer OR 0.89, 0.68–1.15, $p =$
392 0.36) (Gaudet et al., 2015). Conversely, the same pooled analysis found an increased risk for
393 both WC (HR 1.09, 95%CI 1.03–1.16, $p = 0.006$) and WHR (HR 1.17, 95%CI 1.02–1.34, $p =$
394 0.02), mainly in the oral subsite which were not replicated in our MR analysis. Varying
395 patterns of results for these anthropometric measures have been found when stratifying by
396 smoking status within observational studies (Gaudet et al., 2015). The relationship between
397 obesity and HNC is complex. There appears to be a positive association between low BMI
398 (<18.5 kg/m²) and HNC risk, and a protective effect of BMI on HNC risk in current smokers
399 but conversely, a higher risk in never smokers (Gaudet et al., 2015). This suggests smoking
400 is a confounder, both as an established risk factor for HNC and in its correlation with weight,
401 with nicotine affecting metabolic energy expenditure, leading to reduced calorie absorption
402 and appetite suppression (Williamson et al., 1991). Instrument-risk factor effect estimates
403 from this study suggest smoking is also a mediator, through which metabolic traits such as
404 BMI influence HNC risk.

405

406 Despite metabolic syndrome (including hypertension, central obesity, elevated triglyceride,
407 low HDL-C and insulin resistance) being strongly associated with common cancers such as

408 colorectal and breast (Esposito, Chiodini, Colao, Lenzi, & Giugliano, 2012), this does not
409 appear to be the case in head and neck cancer. A recent prospective study of 474,929
410 participants from UK Biobank investigating the effect of metabolic syndrome suggested
411 those with the condition had no increased HNC risk (HR 1.05, 95%CI 0.90–1.22, $p = 0.560$)
412 (Jiang et al., 2021). No definitive causal effects were detected for individual components of
413 metabolic syndrome components either, supporting our MR results. While another large
414 meta-analysis found individuals with T2D have an elevated risk of oral cancer (Gong et al.,
415 2015), other more recent studies have found this effect to be mostly in laryngeal subsite (HR
416 1.25, 95%CI 1.12–1.40) which again we could not investigate in this study (H.-B. Kim et al.,
417 2021). Hypertension is the most consistently reported metabolic trait to have an
418 observational association with HNC risk across the subsites (Christakoudi et al., 2020; H.-B.
419 Kim et al., 2021; S.-Y. Kim et al., 2019; Seo et al., 2020; Stocks et al., 2012). We did not
420 identify a clear effect of either SBP or DBP on oral or oropharyngeal cancer using MR, again
421 suggesting the possibility of residual confounding in observational studies.

422

423 MR was employed in this study in an attempt to overcome the drawbacks of conventional
424 epidemiological studies. However, there are a number of limitations with using this
425 approach and if MR assumptions are violated, this too can generate spurious conclusions.
426 While there was no evidence of weak instrument bias (F statistics > 10), there was
427 heterogeneity present in at least four of the instruments (WHR, T2D, FI and DBP). This is
428 expected to some extent, given that we are instrumenting multiple biological pathways that
429 contribute to complex metabolic phenotypes. The use of multiple related instruments for
430 each metabolic trait may, however, provide some additional confidence in the overall
431 findings. Given the low percentage of variation explained (R^2) for some instruments, as well

432 as the relatively small number of oral and oropharyngeal cancer cases, power to detect an
433 effect may have been an issue in some of our analyses.

434

435 As with observational studies, there may be issues of measurement error or
436 misclassification in genetic epidemiology, given BMI is simply a function of mass and height
437 and does not specifically measure adiposity. However, BMI has been shown to be an
438 acceptable proxy when used in large samples sizes, correlating with both total body fat
439 (Browning et al., 2011) and total abdominal adipose tissue (Ross, Léger, Morris, de Guise, &
440 Guardo, 1992), which is thought to present a greater health risk than fat deposited
441 elsewhere. Furthermore, we used a range of adiposity measures including WC and WHR,
442 which may be better proxies of abdominal adiposity, compared to BMI (C. M. Lee, Huxley,
443 Wildman, & Woodward, 2008). SNPs used to proxy these metabolic traits, particularly
444 obesity-related measures BMI, WC and WHR were strongly associated with smoking. Given
445 the heterogeneity of these complex metabolic traits, future work could further examine
446 their pathway specific effects (Udler et al., 2018).

447

448 **Conclusion**

449

450 Overall, there was limited evidence for an effect of genetically-proxied metabolic traits on
451 oral and oropharyngeal cancer risk. These findings suggest metabolic traits may not be
452 effective modifiable risk factors to prioritise as part of future prevention strategies in head
453 and neck cancer. The effect of metabolic traits on the risk of this disease may have been
454 overestimated in previous observational studies, but these cannot be directly compared

455 given the differences in methodological approaches and the interpretation of estimates.
456 Smoking appears to act as a mediator in the relationship between obesity and HNC.
457 Although there is no clear evidence that changing body mass will reduce or increase the risk
458 of HNC directly, dental and medical teams should be aware of the risk of smoking in those
459 who are overweight and therefore the greater risk of cancer when providing smoking
460 cessation and appropriate weight loss advice.

461

462

463 **References**

464

465 Bowden, J., Davey Smith, G., & Burgess, S. (2015): Mendelian randomization with invalid
466 instruments: effect estimation and bias detection through Egger regression.
467 *International Journal of Epidemiology*, **44**, 512-525.

468 Bowden, J., Del Greco, M. F., Minelli, C., Smith, G. D., Sheehan, N. A., & Thompson, J. R.
469 (2016): Assessing the suitability of summary data for two-sample Mendelian
470 randomization analyses using MR-Egger regression: the role of the I-2 statistic.
471 *International Journal of Epidemiology*, **45**, 1961-1974.

472 Bowden, J., Smith, G. D., Haycock, P. C., & Burgess, S. (2016): Consistent Estimation in
473 Mendelian Randomization with Some Invalid Instruments Using a Weighted Median
474 Estimator. *Genetic Epidemiology*, **40**, 304-314.

475 Bowden, J., Spiller, W., Del Greco, F., Sheehan, N., Thompson, J., Minelli, C., & Smith, G. D.
476 (2018): Improving the visualization, interpretation and analysis of two-sample

- 477 summary data Mendelian randomization via the Radial plot and Radial regression.
478 *International Journal of Epidemiology*, **47**, 1264-1278.
- 479 Brion, M. J., Shakhbazov, K., & Visscher, P. M. (2013): Calculating statistical power in
480 Mendelian randomization studies. *International Journal of Epidemiology*, **42**, 1497-
481 1501.
- 482 Browning, L. M., Mugridge, O., Dixon, A. K., Aitken, S. W., Prentice, A. M., & Jebb, S. A.
483 (2011): Measuring abdominal adipose tissue: comparison of simpler methods with
484 MRI. *Obesity facts*, **4**, 9-15.
- 485 Cao, Z., Li, S., Xu, F., Yang, X., Wang, Y., Zheng, X., & Yang, H. (2020): Association of obesity
486 status and metabolic syndrome with site-specific cancers: a population-based cohort
487 study. *British Journal of Cancer*, **123**, 1336-1344.
- 488 Carreras-Torres, R., Johansson, M., Haycock, P. C., Relton, C. L., Davey Smith, G., Brennan,
489 P., & Martin, R. M. (2018): Role of obesity in smoking behaviour: Mendelian
490 randomisation study in UK Biobank. *BMJ (Clinical research ed.)*, **361**, k1767-k1767.
- 491 Carter, A. R., Borges, M.-C., Benn, M., Tybjaerg-Hansen, A., Davey Smith, G., Nordestgaard,
492 B. G., & Lawlor, D. A. (2019): Combined Association of Body Mass Index and Alcohol
493 Consumption With Biomarkers for Liver Injury and Incidence of Liver Disease: A
494 Mendelian Randomization Study. *JAMA Network Open*, **2**, e190305-e190305.
- 495 Carter, A. R., Gill, D., Davies, N. M., Taylor, A. E., Tillmann, T., Vaucher, J., . . . Dehghan, A.
496 (2019): Understanding the consequences of education inequality on cardiovascular
497 disease: mendelian randomisation study. *BMJ*, **365**, l1855.

- 498 Centers for Disease Control and Prevention. (2021). Obesity and Cancer [Internet] [cited
499 2022 Jun 18]. Retrieved from
500 [https://www.cdc.gov/cancer/obesity/index.htm#:~:text=Being%20overweight%20or](https://www.cdc.gov/cancer/obesity/index.htm#:~:text=Being%20overweight%20or%20having%20obesity,the%20United%20States%20each%20year.)
501 [%20having%20obesity,the%20United%20States%20each%20year.](https://www.cdc.gov/cancer/obesity/index.htm#:~:text=Being%20overweight%20or%20having%20obesity,the%20United%20States%20each%20year.)
- 502 Christakoudi, S., Kakourou, A., Markozannes, G., Tzoulaki, I., Weiderpass, E., Brennan, P., . . .
503 Tsilidis, K. K. (2020): Blood pressure and risk of cancer in the European Prospective
504 Investigation into Cancer and Nutrition. *International Journal of Cancer*, **146**, 2680-
505 2693.
- 506 Consortium, O. (2013): Consortium launches genotyping effort. *Cancer Discov*, **3**, 1321-1322.
- 507 Conway, D. I., Purkayastha, M., Chestnutt, I. G. (2018): The changing epidemiology of oral
508 cancer: definitions, trends, and risk factors. *British Dental Journal*, **225**, 867-873.
- 509 Davey, R. C. (2004): The obesity epidemic: too much food for thought? *British Journal of*
510 *Sports Medicine*, **38**, 360-363.
- 511 Davey Smith, G., & Hemani, G. (2014): Mendelian randomization: genetic anchors for causal
512 inference in epidemiological studies. *Human Molecular Genetics*, **23**, R89-98.
- 513 DeNicola, G. M., & Cantley, L. C. (2015): Cancer's Fuel Choice: New Flavors for a Picky Eater.
514 *Mol Cell*, **60**, 514-523.
- 515 Diaz, Y., Duarte-Salles, T., Recalde, M., Freisling, H., Davila-Batista, V., Leitzmann, M., &
516 Romieu, I. (2021): Body mass index and waist circumference in relation to the risk of
517 26 types of cancer: a prospective cohort study of 3.5 million adults in Spain. *BMC*
518 *Medicine*, **19**, 10-10.

- 519 Dudding, T., Johansson, M., Thomas, S. J., Brennan, P., Martin, R. M., & Timpson, N. J.
520 (2018): Assessing the causal association between 25-hydroxyvitamin D and the risk
521 of oral and oropharyngeal cancer using Mendelian randomization. *International*
522 *Journal of Cancer*, **143**, 1029-1036.
- 523 Esposito, K., Chiodini, P., Colao, A., Lenzi, A., & Giugliano, D. (2012): Metabolic syndrome
524 and risk of cancer: a systematic review and meta-analysis. *Diabetes Care*, **35**, 2402-
525 2411.
- 526 Evangelou, E., Warren, H. R., Mosen-Ansorena, D., Mifsud, B., Pazoki, R., Gao, H., . . . the
527 Million Veteran, P. (2018): Genetic analysis of over 1 million people identifies 535
528 new loci associated with blood pressure traits. *Nature Genetics*, **50**, 1412-1425.
- 529 Gatenby, R. A., & Gillies, R. J. (2004): Why do cancers have high aerobic glycolysis? *Nature*
530 *Reviews Cancer*, **4**, 891-899.
- 531 Gaudet, M. M., Kitahara, C. M., Newton, C. C., Bernstein, L., Reynolds, P., Weiderpass, E., . . .
532 Gapstur, S. M. (2015): Anthropometry and head and neck cancer: a pooled analysis of
533 cohort data. *International Journal of Epidemiology*, **44**, 673-681.
- 534 Gillison, M. L., Chaturvedi, A. K., Anderson, W. F., & Fakhry, C. (2015): Epidemiology of
535 Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. *J Clin*
536 *Oncol*, **33**, 3235-3242.
- 537 Gong, Y., Wei, B., Yu, L., & Pan, W. (2015): Type 2 diabetes mellitus and risk of oral cancer
538 and precancerous lesions: a meta-analysis of observational studies. *Oral Oncology*,
539 **51**, 332-340.

- 540 Gormley, M., Dudding, T., Kachuri, L., Burrows, K., Chong, A. H. W., Martin, R. M., . . .
541 Richmond, R. C. (2022): Investigating the effect of sexual behaviour on
542 oropharyngeal cancer risk: a methodological assessment of Mendelian
543 randomization. *BMC Medicine*, **20**, 40.
- 544 Gormley, M., Yarmolinsky, J., Dudding, T., Burrows, K., Martin, R. M., Thomas, S., . . .
545 Richmond, R. C. (2021): Using genetic variants to evaluate the causal effect of
546 cholesterol lowering on head and neck cancer risk: A Mendelian randomization
547 study. *PLOS Genetics*, **17**, e1009525.
- 548 Gribsholt, S. B., Cronin-Fenton, D., Veres, K., Thomsen, R. W., Ording, A. G., Richelsen, B., &
549 Sorensen, H. T. (2020): Hospital-diagnosed overweight and obesity related to cancer
550 risk: a 40-year Danish cohort study. *Journal of Internal Medicine*, **287**, 435-447.
- 551 Grimberg, A. (2003): Mechanisms by which IGF-I may promote cancer. *Cancer biology &*
552 *therapy*, **2**, 630-635.
- 553 Hartwig, F. P., Smith, G. D., & Bowden, J. (2017): Robust inference in summary data
554 Mendelian randomization via the zero modal pleiotropy assumption. *International*
555 *Journal of Epidemiology*, **46**, 1985-1998.
- 556 Hashibe, M., Brennan, P., Chuang, S. C., Boccia, S., Castellsague, X., Chen, C., . . . Boffetta, P.
557 (2009): Interaction between Tobacco and Alcohol Use and the Risk of Head and Neck
558 Cancer: Pooled Analysis in the International Head and Neck Cancer Epidemiology
559 Consortium. *Cancer Epidemiology Biomarkers & Prevention*, **18**, 541-550.

- 560 Hemani, G., Bowden, J., & Smith, G. D. (2018): Evaluating the potential role of pleiotropy in
561 Mendelian randomization studies. *Human Molecular Genetics*, **27**, R195-R208.
- 562 Jiang, H., Zhou, L., Jiang, K., Huang, X., He, Q., & Yuan, J. (2021): The effect of metabolic
563 syndrome on head and neck cancer incidence risk: a population-based prospective
564 cohort study. *Cancer & metabolism*, **9**, 25-25.
- 565 Johnson, D. E., Burtness, B., Leemans, C. R., Lui, V. W. Y., Bauman, J. E., & Grandis, J. R.
566 (2020): Head and neck squamous cell carcinoma. *Nature Reviews Disease Primers*, **6**,
567 92.
- 568 Karlsson Linner, R., Biroli, P., Kong, E., Meddens, S. F. W., Wedow, R., Fontana, M. A., . . .
569 Beauchamp, J. P. (2019): Genome-wide association analyses of risk tolerance and
570 risky behaviors in over 1 million individuals identify hundreds of loci and shared
571 genetic influences. *Nature Genetics*, **51**, 245-257.
- 572 Kim, H.-B., Kim, G.-J., Han, K.-d., & Joo, Y.-H. (2021): Changes in metabolic syndrome status
573 and risk of laryngeal cancer: A nationwide cohort study. *PLoS One*, **16**, e0252872-
574 e0252872.
- 575 Kim, S.-Y., Han, K.-d., & Joo, Y.-H. (2019): Metabolic Syndrome and Incidence of Laryngeal
576 Cancer: A Nationwide Cohort Study. *Scientific Reports*, **9**, 667.
- 577 Lagou, V., Mägi, R., Hottenga, J.-J., Grallert, H., Perry, J. R. B., Bouatia-Naji, N., . . . Insulin-
578 related traits, C. (2021): Sex-dimorphic genetic effects and novel loci for fasting
579 glucose and insulin variability. *Nature Communications*, **12**, 24.

- 580 Lawlor, D. A., Harbord, R. M., Sterne, J. A., Timpson, N., & Davey Smith, G. (2008):
581 Mendelian randomization: using genes as instruments for making causal inferences
582 in epidemiology. *Statistics in Medicine*, **27**, 1133-1163.
- 583 Lawlor DA, W. K., Borges MC, Palmer T, Hartwig FP, Hemani G, Bowden JA. . (2019): A
584 Mendelian Randomization dictionary: Useful definitions and descriptions for
585 undertaking, understanding and interpreting Mendelian Randomization studies.
- 586 Lee, C. M., Huxley, R. R., Wildman, R. P., & Woodward, M. (2008): Indices of abdominal
587 obesity are better discriminators of cardiovascular risk factors than BMI: a meta-
588 analysis. *J Clin Epidemiol*, **61**, 646-653.
- 589 Lee, J., Wedow, R., Okbay, A., Kong, E., Maghziyan, O., Zacher, M., . . . Social Science Genetic
590 Association, C. (2018): Gene discovery and polygenic prediction from a genome-wide
591 association study of educational attainment in 1.1 million individuals. *Nature*
592 *Genetics*, **50**, 1112-1121.
- 593 Lesueur, C., Diergaarde, B., Olshan, A. F., Wunsch, V., Ness, A. R., Liu, G., . . . Brennan, P.
594 (2016): Genome-wide association analyses identify new susceptibility loci for oral
595 cavity and pharyngeal cancer. *Nature Genetics*, **48**, 1544-1550.
- 596 Liu, M. Z., Jiang, Y., Wedow, R., Li, Y., Brazel, D. M., Chen, F., . . . Psychiat, H. A. I. (2019):
597 Association studies of up to 1.2 million individuals yield new insights into the genetic
598 etiology of tobacco and alcohol use. *Nature Genetics*, **51**, 237.
- 599 Pers, T. H., Timshel, P., & Hirschhorn, J. N. (2014): SNPsnap: a Web-based tool for
600 identification and annotation of matched SNPs. *Bioinformatics*, **31**, 418-420.

- 601 Pulit, S. L., Stoneman, C., Morris, A. P., Wood, A. R., Glastonbury, C. A., Tyrrell, J., . . .
602 Lindgren, C. M. (2019): Meta-analysis of genome-wide association studies for body
603 fat distribution in 694 649 individuals of European ancestry. *Human Molecular*
604 *Genetics*, **28**, 166-174.
- 605 Ross, R., Léger, L., Morris, D., de Guise, J., & Guardo, R. (1992): Quantification of adipose
606 tissue by MRI: relationship with anthropometric variables. *J Appl Physiol* (1985), **72**,
607 787-795.
- 608 Saarela, K., Tuomilehto, J., Sund, R., Keskimaki, I., Hartikainen, S., & Pukkala, E. (2019):
609 Cancer incidence among Finnish people with type 2 diabetes during 1989-2014.
610 *European Journal of Epidemiology*, **34**, 259-265.
- 611 Sanderson, E., Glymour, M. M., Holmes, M. V., Kang, H., Morrison, J., Munafò, M. R., . . .
612 Davey Smith, G. (2022): Mendelian randomization. *Nature Reviews Methods Primers*,
613 **2**, 6.
- 614 Seo, J.-H., Kim, Y.-D., Park, C.-S., Han, K.-d., & Joo, Y.-H. (2020): Hypertension is associated
615 with oral, laryngeal, and esophageal cancer: a nationwide population-based study.
616 *Scientific Reports*, **10**, 10291.
- 617 Shungin, D., Winkler, T. W., Croteau-Chonka, D. C., Ferreira, T., Locke, A. E., Mägi, R., . . .
618 Mohlke, K. L. (2015): New genetic loci link adipose and insulin biology to body fat
619 distribution. *Nature*, **518**, 187-196.

- 620 Smith, G. D., & Ebrahim, S. (2003): 'Mendelian randomization': can genetic epidemiology
621 contribute to understanding environmental determinants of disease? *International*
622 *Journal of Epidemiology*, **32**, 1-22.
- 623 Stocks, T., Van Hemelrijck, M., Manjer, J., Bjorge, T., Ulmer, H., Hallmans, G., . . . Stattin, P.
624 (2012): Blood pressure and risk of cancer incidence and mortality in the Metabolic
625 Syndrome and Cancer Project. *Hypertension (Dallas, Tex. : 1979)*, **59**, 802-810.
- 626 Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F.
627 (2021): Global cancer statistics 2020: GLOBOCAN estimates of incidence and
628 mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for*
629 *Clinicians*.
- 630 Thomas, S. J., Penfold, C. M., Waylen, A., & Ness, A. R. (2018): The changing aetiology of
631 head and neck squamous cell cancer: A tale of three cancers? *Clinical*
632 *Otolaryngology*, **43**, 999-1003.
- 633 Tseng, K. S., Lin, C., Lin, Y. S., & Weng, S. F. (2014): Risk of head and neck cancer in patients
634 with diabetes mellitus: a retrospective cohort study in Taiwan. *JAMA Otolaryngol*
635 *Head Neck Surg*, **140**, 746-753.
- 636 Udler, M. S., Kim, J., von Grotthuss, M., Bonàs-Guarch, S., Cole, J. B., Chiou, J., . . . Florez, J.
637 C. (2018): Type 2 diabetes genetic loci informed by multi-trait associations point to
638 disease mechanisms and subtypes: A soft clustering analysis. *PLoS Med*, **15**,
639 e1002654.

- 640 Verbanck, M., Chen, C. Y., Neale, B., & Do, R. (2018): Publisher Correction: Detection of
641 widespread horizontal pleiotropy in causal relationships inferred from Mendelian
642 randomization between complex traits and diseases. *Nature Genetics*, **50**, 1196.
- 643 Vujkovic, M., Keaton, J. M., Lynch, J. A., Miller, D. R., Zhou, J., Tcheandjieu, C., . . . Program,
644 V. A. M. V. (2020): Discovery of 318 new risk loci for type 2 diabetes and related
645 vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis.
646 *Nature Genetics*, **52**, 680-691.
- 647 Wald, A. (1940): The Fitting of Straight Lines if Both Variables are Subject to Error. *The*
648 *Annals of Mathematical Statistics*, **11**, 284-300, 217.
- 649 Ward, H. A., Wark, P. A., Muller, D. C., Steffen, A., Johansson, M., Norat, T., . . . Riboli, E.
650 (2017): Measured Adiposity in Relation to Head and Neck Cancer Risk in the
651 European Prospective Investigation into Cancer and Nutrition. *Cancer epidemiology,*
652 *biomarkers & prevention : a publication of the American Association for Cancer*
653 *Research, cosponsored by the American Society of Preventive Oncology*, **26**, 895-904.
- 654 Wheeler, E., Leong, A., Liu, C. T., Hivert, M. F., Strawbridge, R. J., Podmore, C., . . . Meigs, J.
655 B. (2017): Impact of common genetic determinants of Hemoglobin A1c on type 2
656 diabetes risk and diagnosis in ancestrally diverse populations: A transethnic genome-
657 wide meta-analysis. *PLoS Med*, **14**, e1002383.
- 658 Williamson, D. F., Madans, J., Anda, R. F., Kleinman, J. C., Giovino, G. A., & Byers, T. (1991):
659 Smoking Cessation and Severity of Weight Gain in a National Cohort. *New England*
660 *Journal of Medicine*, **324**, 739-745.

661 Wootton, R. E., Richmond, R. C., Stuijzand, B. G., Lawn, R. B., Sallis, H. M., Taylor, G. M. J., . .
662 . Munafo, M. R. (2019): Evidence for causal effects of lifetime smoking on risk for
663 depression and schizophrenia: a Mendelian randomisation study. *Psychol Med*, 1-9.

664 World Health Organization (WHO). (2022). WHO European Regional Obesity Report 2022.
665 [Internet] [cited 2022 Jun 06].

666

667 **Ethics approval and consent to participate**

668 All studies included as part of the GAME-ON network obtained approval and consent from
669 their respective institutions.

670

671 **Consent for publication**

672 Not applicable.

673

674 **Availability of data and materials**

675 Summary-level analysis was conducted using publicly available GWAS data as cited. Full
676 summary statistics for the GAME-ON outcome data GWAS can be accessed via dbGAP
677 (OncoArray: Oral and Pharynx Cancer; study accession number: phs001202.v1.p1, August
678 2017) at: [https://www.ncbi.nlm.nih.gov/projects/gap/cgi-](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001202.v1.p1)
679 [bin/study.cgi?study_id=phs001202.v1.p1](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001202.v1.p1)) (Lesseur et al., 2016). This data is also available
680 via the IEU OpenGWAS project (<https://gwas.mrcieu.ac.uk/>).

681

682 All exposure data used in this study is publicly available from the relevant studies as
683 described below. Data for BMI, WC and WHR GWAS was downloaded from the
684 Genetic Investigation of ANthropometric Traits (GIANT) consortium
685 [https://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_f](https://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_files)
686 [iles](https://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_files) (Pulit et al., 2019; Shungin et al., 2015) and UK Biobank (<http://www.ukbiobank.ac.uk>).
687 T2D data was downloaded from the DIAMANTE (DIAbetes Meta-ANalysis of Trans-Ethnic
688 association studies) consortium from: <https://kp4cd.org/node/169> (Vujkovic et al., 2020).
689 Data for FG, FI and HbA_{1c}, were obtained from GWAS published by the MAGIC (Meta-
690 Analyses of Glucose and Insulin-Related Traits) Consortium, available for download from:
691 <https://magicinvestigators.org/downloads/> (Lagou et al., 2021). Finally, data for SBP and
692 DBP were extracted from a GWAS meta-analysis of participants in UK Biobank
693 <http://www.ukbiobank.ac.uk>) and the International Consortium of Blood Pressure Genome
694 Wide Association Studies (ICBP), available via dbGAP (International Consortium for Blood
695 Pressure (ICBP), study accession number: phs000585.v2.p1, October 2016) at
696 https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000585.v2.p1
697 (Evangelou et al., 2018).
698
699 Instrument-risk factor analysis outcome summary-level data were derived from the GWAS &
700 Sequencing Consortium of Alcohol and Nicotine use (GSCAN) and UK Biobank and UK
701 Biobank (<http://www.ukbiobank.ac.uk>) for alcoholic drinks per week
702 <https://conservancy.umn.edu/handle/11299/201564> (Liu et al., 2019) and the
703 comprehensive smoking index (Wootton et al., 2019). Data for risk tolerance and
704 educational attainment were taken from Social Science Genetic Association Consortium
705 (SSGAC) data available from <http://www.thessgac.org/data> (Karlsson Linner et al., 2019; J.

706 Lee et al., 2018). MR analyses were conducted using the “TwoSampleMR” package in R
707 (version 3.5.3). A copy of the code and all data files used in this study are available at GitHub
708 (https://github.com/MGormley12/metabolic_trait_hnc_mr.git).

709

710 **Competing interests**

711 The authors declare that they have no competing interests

712

713 **Funding**

714 M.G. was a National Institute for Health Research (NIHR) academic clinical fellow and is
715 currently supported by a Wellcome Trust GW4-Clinical Academic Training PhD Fellowship.

716 This research was funded in part, by the Wellcome Trust [Grant number 220530/Z/20/Z].

717 For the purpose of open access, the author has applied a CC BY public copyright licence to

718 any Author Accepted Manuscript version arising from this submission. R.C.R. is a de Pass VC

719 research fellow at the University of Bristol. J.T. is supported by an Academy of Medical

720 Sciences (AMS) Springboard award, which is supported by the AMS, the Wellcome Trust,

721 Global Challenges Research Fund (GCRF), the Government Department of Business, Energy

722 and Industrial strategy, the British Heart Foundation and Diabetes UK (SBF004\1079). A.R.N.

723 was supported by the National Institute for Health Research (NIHR) Bristol Biomedical

724 Research Centre which is funded by the National Institute for Health Research (NIHR) and is

725 a partnership between University Hospitals Bristol NHS Foundation Trust and the University

726 of Bristol. Department of Health and Social Care disclaimer: The views expressed are those

727 of the authors and not necessarily those of the NHS, the NIHR or the Department of Health

728 and Social Care. This publication presents data from the Head and Neck 5000 which

729 contributes to international VOYAGER and HEADSpAcE head and neck cancer consortia. The

730 Head and Neck 5000 study was a component of independent research funded by the
731 National Institute for Health Research (NIHR) under its Programme Grants for Applied
732 Research scheme (RP-PG-0707-10034). The views expressed in this publication are those of
733 the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.
734 Core funding was also provided through awards from Above and Beyond, University
735 Hospitals Bristol and Weston Research Capability Funding and the NIHR Senior Investigator
736 award to A.R.N. Human papillomavirus (HPV) serology was supported by a Cancer Research
737 UK Programme Grant, the Integrative Cancer Epidemiology Programme (C18281/A20919).
738 The VOYAGER study was supported in part by the US National Institute of Dental and
739 Craniofacial Research (NIDCR; R01 DE025712). The genotyping of the HNC cases and
740 controls was performed at the Center for Inherited Disease Research (CIDR) and funded by
741 the US National Institute of Dental and Craniofacial Research (NIDCR; 1X01HG007780-0).
742 E.E.V, C.B. and D.L. are supported by Diabetes UK (17/0005587). E.E.V, and C.B. are
743 supported by the World Cancer Research Fund (WCRF UK), as part of the World Cancer
744 Research Fund International grant programme (IIG_2019_2009). M.G., T.D., G.D.S, E.E.V.,
745 R.C.R, and C.B. are part of the Medical Research Council Integrative Epidemiology Unit at
746 the University of Bristol supported by the Medical Research Council (MC_UU_00011/1,
747 MC_UU_00011/5, MC_UU_00011/6, MC_UU_00011/7).